These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 24004347)

  • 1. Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications.
    Setyawan J; Guérin A; Hodgkins P; Gauthier G; Cloutier M; Wu E; Erder MH
    J Med Econ; 2013 Nov; 16(11):1275-89. PubMed ID: 24004347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis.
    Setyawan J; Hodgkins P; Guérin A; Gauthier G; Cloutier M; Wu EQ; Erder MH
    J Med Econ; 2013 Jul; 16(7):962-75. PubMed ID: 23621503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults.
    Setyawan J; Hodgkins P; Guérin A; Gauthier G; Cloutier M; Wu E; Erder MH
    J Med Econ; 2013 Oct; 16(10):1203-15. PubMed ID: 23937642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity.
    Erder MH; Signorovitch JE; Setyawan J; Yang H; Parikh K; Betts KA; Xie J; Hodgkins P; Wu EQ
    J Med Econ; 2012; 15(6):1078-87. PubMed ID: 22537226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Examining the heterogeneity of treatment patterns in attention deficit hyperactivity disorder among children and adolescents in the Texas Medicaid population: modeling suboptimal treatment response.
    Grebla R; Setyawan J; Park C; Richards KM; Nwokeji ED; Pawaskar M; Haim Erder M; Lawson KA
    J Med Econ; 2019 Aug; 22(8):788-797. PubMed ID: 30983465
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population.
    Hodgkins P; Sasané R; Christensen L; Harley C; Liu F
    Curr Med Res Opin; 2011; 27 Suppl 2():53-62. PubMed ID: 21973231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization patterns of stimulants in ADHD in the Medicaid population: a retrospective analysis of data from the Texas Medicaid program.
    Lawson KA; Johnsrud M; Hodgkins P; Sasané R; Crismon ML
    Clin Ther; 2012 Apr; 34(4):944-956.e4. PubMed ID: 22444786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
    Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J
    Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
    Wu EQ; Birnbaum HG; Zhang HF; Ivanova JI; Yang E; Mallet D
    J Manag Care Pharm; 2007 Sep; 13(7):561-9. PubMed ID: 17874862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.
    Christensen L; Sasané R; Hodgkins P; Harley C; Tetali S
    Curr Med Res Opin; 2010 Apr; 26(4):977-89. PubMed ID: 20178404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing a Risk Score to Guide Individualized Treatment Selection in Attention Deficit/Hyperactivity Disorder.
    Setyawan J; Yang H; Cheng D; Cai X; Signorovitch J; Xie J; Erder MH
    Value Health; 2015 Sep; 18(6):824-31. PubMed ID: 26409610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study.
    Babcock T; Dirks B; Adeyi B; Scheckner B
    BMC Pharmacol Toxicol; 2012 Dec; 13():18. PubMed ID: 23254273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial.
    Coghill DR; Banaschewski T; Lecendreux M; Zuddas A; Dittmann RW; Otero IH; Civil R; Bloomfield R; Squires LA
    Eur Child Adolesc Psychiatry; 2014 Feb; 23(2):61-8. PubMed ID: 23708466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
    Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
    Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medication use in adults with attention deficit/hyperactivity disorder in a commercially-insured population in the United States.
    Zhou Z; Zhou ZY; Kelkar SS; Sikirica V; Xie J; Grebla R
    Curr Med Res Opin; 2018 Apr; 34(4):585-592. PubMed ID: 29186993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder.
    Brams M; Mao AR; Doyle RL
    Postgrad Med; 2008 Sep; 120(3):69-88. PubMed ID: 18824827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.